{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:25Z","timestamp":1793136985089,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.amjcard.2024.12.024","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T17:53:39Z","timestamp":1735062819000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"239","author":[{"given":"Ashraf","family":"Samhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-7539","authenticated-orcid":false,"given":"Danish","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmeen","family":"Bindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljash","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic E.","family":"Fullenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Baldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothy J.","family":"Puthumana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.12.024_bib0001","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0002","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012250","article-title":"Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA","volume":"8","author":"Massera","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0004","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0008","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0005","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003132","article-title":"Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0010","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.21037\/jtd-22-182","article-title":"Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review","volume":"14","author":"Guigui","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0013","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0011","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.31083\/j.rcm2204151","article-title":"A systematic review and pooled analysis of septal myectomy and edge-to-edge mitral valve repair in obstructive hypertrophic cardiomyopathy","volume":"22","author":"Mihos","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0012","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.echo.2015.07.002","article-title":"Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy","volume":"28","author":"Halpern","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4244\/EIJ-D-18-00959","article-title":"Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal","volume":"15","author":"Pelliccia","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ccd.20500","article-title":"Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique","volume":"66","author":"Holmes","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0016","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","article-title":"A phase 1 dose-escalation study of the cardiac myosin inhibitor Aficamten in healthy participants","volume":"7","author":"Malik","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0017","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0018","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0019","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0023","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0020","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hedge","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.12.024_bib0021","unstructured":"Reuters. FDA approves Bristol Myers\u2019 oral heart disease drug. Available at:https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/fda-approves-bristol-myers-heart-disease-drug-2022-04-29\/. Accessed on January 3, 2025."},{"key":"10.1016\/j.amjcard.2024.12.024_bib0025","unstructured":"Wasfy JH, Walton SM, Beinfeld M, Nhan E, Sarker J, Whittington MD, Pearson SD, Rind DM. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; final evidence report and meeting summary. Institute for Clinical and Economic Review. Available at: https:\/\/icer.org\/hypertrophic-cardiomyopathy-2021\/. Accessed on January 3, 2025."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924008828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924008828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:13:07Z","timestamp":1740057187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924008828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"alternative-id":["S0002914924008828"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.12.024","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}